Description: Polydex Pharmaceuticals Limited is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Its principal business activities, carried on through subsidiaries, include the manufacture and sale of veterinary pharmaceutical products and specialty chemicals. The Company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company conducts its business operations through its two subsidiaries: Dextran Products Limited and Chemdex, Inc. Dextran Products Limited manufactures and sells Dextran and Dextran derivative products, including Iron Dextran. Chemdex, Inc. sells Iron Dextran for the United States market.
Home Page: www.polydex.com
421 Comstock Road
Toronto,
ON
M1L 2H5
Canada
Phone:
416 755 2231
Officers
| Name | Title |
|---|---|
| Mr. George G. Usher | Chairman, CEO & Pres |
| Ms. Sharon L. Wardlaw | COO, Treasurer & Sec. |
| Mr. David P. Jamestee C.A., CPA | Chief Financial Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.418 |
| Price-to-Sales TTM: | 0.5061 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 21 |